Breaking News Instant updates and real-time market news.

ISR

IsoRay

$0.34

-0.0079 (-2.26%)

08:32
08/13/19
08/13
08:32
08/13/19
08:32

IsoRay says efficacy of Cesium Blu shown in recent studies

Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Cesium Blu is making an important difference in providing treatment options for cancer patients and their doctors. Isoray expects the growing volume of results-based data on Cesium Blu, formerly known as Cesium-131, will help grow market awareness of the range of clinical applications. Among the recent studies are the findings of Dr. David Brachman of the Barrow Neuroscience Institute on the impact of Cesium Blu-driven treatment on three types of recurrent brain cancers. According to the publication, Surgically Targeted Radiation Therapy: Safety Profile of Collagen Tile Brachytherapy in 79 Recurrent, Previously Irradiated Intracranial Neoplasms on a Prospective Clinical Trial, Cesium-powered GammaTile therapy offers recurrent brain cancer patients a safe and effective treatment. The findings involve patients suffering from high grade gliomas, meningiomas and brain metastases. The results are important because recurrence of these hard to treat brain cancers have left patients with very limited options due to their prior radiation treatments. FDA cleared in July 2018, GammaTile therapy offers promising treatment for patients with these brain cancers. Another recent study, Long Term Results from a Prospective Randomized Trial of 131Cs vs 125I Permanent Prostate Brachytherapy, was published by Dr. Manui Agarwal of the University of Maryland and Dr. Brian Moran of the Chicago Prostate Cancer Center. It reported long-term follow-up data collected on Cesium-131 as compared to Iodine-125, a long-established prostate brachytherapy isotope. This long-term data with nine-year median follow-up shows comparable long-term biochemical control results between Cesium-131 and Iodine-125 in these patients. The data supports Cesium-131 as an effective long-term solution for these patients and supports Cesium-131 as an optimal choice for prostate cancer patients. The impact of Cesium-131 on recurring skull base (deep neck) cancers is the focus of a case report in the Journal of Neurological Surgery Reports by Dr. Corey Savard of Thomas Jefferson University Hospital. The joint effort of otolaryngology, radiation oncology and neurosurgical physicians is entitled, Cesium-131 Interstitial Brachytherapy for Recurrent Malignancies of the Skull Base. Presented were two cases of the especially challenging cancers that recur in a very difficult area to treat. The authors stated that the characteristics of Cesium-131 that make it effective in treating other cancers might also make it effective in treating difficult recurring skull base malignancies. Although this is a small study and the results are early, as of the published date there were no recurrences or complications noted in either case.

ISR IsoRay
$0.34

-0.0079 (-2.26%)

11/09/18
MAXM
11/09/18
DOWNGRADE
MAXM
Hold
IsoRay downgraded to Hold from Buy at Maxim
11/09/18
MAXM
11/09/18
DOWNGRADE
MAXM
Hold
IsoRay downgraded to Hold from Buy at Maxim
As reported earlier, Maxim analyst Jason McCarthy downgraded IsoRay to Hold from Buy after its Q4 results saw a sequential decline of 2.5%. The analyst maintains his view that the company's "Cs-131 is a superior isotope for radio-therapy", but also notes that it continues to struggle to drive revenue growth. McCarthy adds that it is too early to tell whether its GammaTile be the answer, but only sees incremental revenue growth from the program.
01/28/19
HCWC
01/28/19
INITIATION
Target $0.7
HCWC
Buy
IsoRay assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of IsoRay with a Buy rating and 70c price target. The company is at an inflection point of sustainable revenue growth, Ramakanth tells investors in a research note. He views the company as as a turnaround story.
02/13/19
HCWC
02/13/19
NO CHANGE
HCWC
H.C. Wainwright reiterates Buy on IsoRay after Q2 results
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and 70c price target on IsoRay following the company's Q2 results, which slightly beat the firm's estimate on revenue and was in-line on net loss per share. The analyst noted that double digit revenue growth continued for the seventh consecutive quarter and believes "the current strong momentum of revenue growth could be sustained by upcoming full launches of Blu Build and GammaTile." Ramakanth also believes the company's $7.9M in cash and cash equivalents should be sufficient to fund it into Q2 of FY20.

TODAY'S FREE FLY STORIES

EL

Estee Lauder

$201.74

22.48 (12.54%)

07:37
08/20/19
08/20
07:37
08/20/19
07:37
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

VVUS

VIVUS

$3.46

-0.02 (-0.57%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Hot Stocks
VIVUS says study shows addition of Qsymia to LSG surgery improved weight loss »

VIVUS announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$125.55

0.73 (0.58%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 15

    Oct

TPIC

TPI Composites

$17.49

-0.2 (-1.13%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Upgrade
TPI Composites rating change  »

TPI Composites upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

PVTL

Pivotal Software

$13.85

-0.16 (-1.14%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

07:35
08/20/19
08/20
07:35
08/20/19
07:35
General news
Treasury Market Outlook: Treasuries are back in rally mode »

Treasury Market Outlook:…

DOW

Dow Inc.

$45.58

1.09 (2.45%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Hot Stocks
Dow Inc. to retrofit Louisiana cracker with FCDh technology to produce propylene »

Dow announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Oct

LULU

Lululemon

$178.63

0.83 (0.47%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
Lululemon analyst commentary  »

Lululemon earnings and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EVER

EverQuote

$22.18

0.88 (4.13%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
EverQuote analyst commentary  »

EverQuote price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITRI

Itron

$70.02

0.3 (0.43%)

07:33
08/20/19
08/20
07:33
08/20/19
07:33
Downgrade
Itron rating change  »

Itron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BIIB

Biogen

$235.61

4.05 (1.75%)

, NVTA

Invitae

$25.78

0.6 (2.38%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Biogen, Invitae announce availability of SMA STAT test »

Biogen (BIIB) and Invitae…

BIIB

Biogen

$235.61

4.05 (1.75%)

NVTA

Invitae

$25.78

0.6 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

MBRX

Moleculin Biotech

$1.15

0.07 (6.48%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Moleculin Biotech receives Emory University CTRC approval for WP1066 trial »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$74.86

1.6 (2.18%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Hot Stocks
Qualcomm, LGE enter new global patent license agreement »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

CRM

Salesforce

$143.66

-0.23 (-0.16%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

HAIN

Hain Celestial

$21.88

0.14 (0.64%)

07:28
08/20/19
08/20
07:28
08/20/19
07:28
Downgrade
Hain Celestial rating change  »

Hain Celestial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 15

    Sep

VNO

Vornado

$61.34

0.14 (0.23%)

07:26
08/20/19
08/20
07:26
08/20/19
07:26
Downgrade
Vornado rating change  »

Vornado downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MKC

McCormick

$168.53

-1.585 (-0.93%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
McCormick rating change  »

McCormick downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$54.67

2.28 (4.35%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
Las Vegas Sands rating change  »

Las Vegas Sands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$207.98

4.335 (2.13%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Home Depot analyst commentary  »

Home Depot Q2 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CSCO

Cisco

$48.50

1.54 (3.28%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Cisco analyst commentary  »

Cisco 'sum of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 10

    Oct

  • 13

    Nov

RGNX

Regenxbio

$37.50

0.27 (0.73%)

, ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Upgrade
Regenxbio, Adverum Biotechnologies rating change  »

Regenxbio upgraded to…

RGNX

Regenxbio

$37.50

0.27 (0.73%)

ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 11

    Sep

SILK

Silk Road Medical

$40.85

0.28 (0.69%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Initiation
Silk Road Medical initiated  »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTX

Entera Bio

$2.30

-0.24 (-9.45%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Hot Stocks
Entera Bio to report results from Phase 2b study for oral PTH in September »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CPB

Campbell Soup

$43.17

0.53 (1.24%)

07:22
08/20/19
08/20
07:22
08/20/19
07:22
Upgrade
Campbell Soup rating change  »

Campbell Soup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 01

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.